EGFR and lung cancer: Fiala O et al [13] evaluated the effect of second-line pemetrexed with third-line erlotinib on advanced-stage (IIIB/IV) lung cancer with wild-type EGFR gene, indicating significant improvement of both PFS and overall survival for patients sequentially treated with erlotinib and pemetrexed compared with the pemetrexed-erlotinib sequence.